



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				Complete if Known			
LIST OF INFORMATION CITED BY APPLICANT (Use as many sheets as necessary)				Application Number	10/650,260		
				Filing Date	August 27, 2003		
				First Named Inventor	Poynard		
				Group Art Unit	Unassigned		
				Examiner Name	Unassigned		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
JSB	*A1	5,935,798	08/10/1999	Price et al.	435	7.23	
JSB	*A2	4,312,853	01/26/1982	Timpl	424	1	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
JSB	*A3	EP 0 911 343 A2	04/28/1999	Tosoh Corporation			
JSB	*A4	WO 01/86304 A2	11/15/2001	Bayer Aktiengesellschaft			
<b>NON-PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
JSB	*A5	Bedossa et al., "Apolipoprotein AI is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients." <i>Alcohol Clin. Exp. Res.</i> 13(6):829-833 (November/December 1989)					
JSB	*A6	Gabielli et al., "Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis." <i>Clin. Chim. Acta</i> 265:21-31 (1997)					
JSB	*A7	Guechot et al., "Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis." <i>Clin Chem.</i> 42(4):558-563 (1996)					
JSB	*A8	Johnston, "Special Considerations in Interpreting Liver Function Tests." <i>Am. Fam. Physician</i> pp. 1-11 (April 15, 1999) <a href="http://www.aafp.org/afp/990415ap/2223.html">www.aafp.org/afp/990415ap/2223.html</a> (Print Date of February 8, 2002)					
JSB	*A9	Kasahara et al., "Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response." <i>J. Hepatol.</i> 26(3):574-583 (March 1997)					
JSB	*A10	Kropf et al., "Efficacy of Serum Laminin Measurement for Diagnosis of Fibrotic Liver Diseases." <i>Clin. Chem.</i> 34(10):2026-2030 (1988)					
JSB	*A11	Naveau et al., "Alpha-2-Macroglobulin and Hepatic Fibrosis. Diagnostic Interest." <i>Dig. Dis. Sci.</i> 39(11):2426-2432 (November 1994)					
JSB	*A12	Oberti et al., "Noninvasive Diagnosis of Hepatic Fibrosis or Cirrhosis." <i>Gastroenterology</i> 113(5):1609-1616 (November 1997)					
JSB	*A13	Pilette et al., "Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers." <i>J. Hepatol.</i> 28(3):439-446 (March 1998)					
no copy provided	*A14	Poynard and Bedossa, "Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus." METAVIR and CLINIVIR Cooperative Study Groups. <i>J. Viral Hepat.</i> 4(3):199-208 (May 1997)					



ATTORNEY DOCKET NO. 03225.0001U2  
APPLICATION NO. 10/650,260  
SHEET 2 OF 2

JSB	*A15	Poynard et al., "Natural history of liver fibrosis progression in patients with chronic hepatitis C." The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. <i>Lancet</i> 349(9055):825-832 (March 22, 1997)
JSB	*A16	Teare et al., "Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis." <i>Lancet</i> 342:895-898 (October 9, 1993)
JSB	*A17	Wong et al., "Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection." <i>J. Viral Hepat.</i> 5:187-192 (May 1998)
Examiner Signature: /John S. Brusca/ Date Considered: 06/25/2006		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		